Telomeres and telomerase as novel drug targets: Reflections on the 2009 Nobel Prize in Physiology or Medicine

European Journal of Clinical Pharmacology

Volumn 66, Issue 1, 2010, Pages 1-3

  Dong, Meng ^a   Mürdter, Thomas E ^a   Klotz, Ulrich ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; CANCER VACCINE; OLIGOMER; PEPTIDE NUCLEIC ACID; PEPTIDE VACCINE; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME; CORRELATION ANALYSIS; DNA SEQUENCE; DRUG TARGETING; EDITORIAL; EMBRYO DEVELOPMENT; ENZYME DEGRADATION; ENZYME INHIBITION; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA INTERFERENCE; TELOMERE;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICINE; NOBEL PRIZE; PHYSIOLOGY; TELOMERASE; TELOMERE;

EID: 76949088999     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0758-9     Document Type: Editorial

References (21)

1. JW Szostak EH Blackburn 1982 Cloning yeast telomeres on linear plasmid vectors Cell 29 245 255 10.1016/0092-8674(82)90109-X 1:CAS:528: DyaL38XktlCisbg%3D 6286143
2. CW Greider EH Blackburn 1987 The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity Cell 51 887 898 10.1016/0092-8674(87)90576-9 1:CAS:528:DyaL1cXptVKhsQ%3D%3D 3319189
3. MN Helder GB Wisman GJ van der Zee 2002 Telomerase and telomeres: from basic biology to cancer treatment Cancer Invest 20 82 101 10.1081/CNV-120000370 1:CAS:528:DC%2BD38XitFOmsr8%3D 11855380
4. SA Stewart RA Weinberg 2006 Telomeres: cancer to human aging Annu Rev Cell Dev Biol 22 531 557 10.1146/annurev.cellbio.22.010305.104518 1:CAS:528:DC%2BD28Xht1yjs7jE 16824017 (Pubitemid 44778007)
5. CB Harley AB Futcher CW Greider 1990 Telomeres shorten during ageing of human fibroblasts Nature 345 458 460 10.1038/345458a0 1:CAS:528: DyaK3cXksFKntb4%3D 2342578 (Pubitemid 20178256)
6. RT Calado NS Young 2008 Telomere maintenance and human bone marrow failure Blood 111 4446 4455 10.1182/blood-2007-08-019729 1:CAS:528: DC%2BD1cXlsVSku7w%3D 18239083
7. PM Lansdorp 2009 Telomeres and disease EMBO J 28 2532 2540 10.1038/emboj.2009.172 1:CAS:528:DC%2BD1MXotVSns70%3D 19629041
8. M Kirwan I Dokal 2008 Dyskeratosis congenita: a genetic disorder of many faces Clin Genet 73 103 112 10.1111/j.1399-0004.2007.00923.x 1:CAS:528:DC%2BD1cXhsV2ht7nJ 18005359
9. AM Rankin DV Faller RA Spanjaard 2008 Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity Anticancer Drugs 19 329 338 10.1097/CAD.0b013e3282f5d4c2 1:CAS:528: DC%2BD1cXjvFems7c%3D 18454043
10. E Kleideiter K Piotrowska U Klotz 2007 Screening of telomerase inhibitors Methods Mol Biol 405 167 180 10.1007/978-1-60327-070-0-13 1:CAS:528: DC%2BD1cXmsFOisg%3D%3D 18369824
11. H Chen Y Li TO Tollefsbol 2009 Strategies targeting telomerase inhibition Mol Biotechnol 41 194 199 10.1007/s12033-008-9117-9 1:CAS:528: DC%2BD1MXntFChsQ%3D%3D 18956258
12. E Pascolo C Wenz J Lingner N Hauel H Priepke I Kauffmann P Garin-Chesa WJ Rettig K Damm A Schnapp 2002 Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate J Biol Chem 277 15566 15572 10.1074/jbc.M201266200 1:CAS:528:DC%2BD38Xjs1Wjsrw%3D 11854300 (Pubitemid 34967825)
13. Y Kakiuchi N Sasaki M Satoh-Masuoka H Murofushi K Murakami-Murofushi 2004 A novel pyrazolone, 4, 4-dichloro-1-(2, 4-dichlorophenyl)-3-methyl-5- pyrazolone, as a potent catalytic inhibitor of human telomerase Biochem Biophys Res Commun 320 1351 1358 10.1016/j.bbrc.2004.06.094 1:CAS:528: DC%2BD2cXls1eitr4%3D 15303281 (Pubitemid 38916692)
14. J Beisner M Dong S Taetz N Nafee EU Griese U Schaefer CM Lehr U Klotz TE Mürdter 2009 Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells Lung Cancer 10.1016/j.lungcan.2009.07.010 19695733
15. CB Harley 2008 Telomerase and cancer therapeutics Nat Rev Cancer 8 167 179 10.1038/nrc2275 1:CAS:528:DC%2BD1cXitlOjuro%3D 18256617 (Pubitemid 351305939)
16. GL Beatty RH Vonderheide 2008 Telomerase as a universal tumor antigen for cancer vaccines Expert Rev Vaccines 7 881 887 10.1586/14760584.7.7.881 1:CAS:528:DC%2BD1cXhtVOiur%2FN 18767939
17. P Nava-Parada LA Emens 2007 GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers Curr Opin Mol Ther 9 490 497 1:CAS:528:DC%2BD2sXhtlertbfE 17932813
18. JL Mergny JF Riou P Mailliet MP Teulade-Fichou E Gilson 2002 Natural and pharmacological regulation of telomerase Nucleic Acids Res 30 839 865 10.1093/nar/30.4.839 1:CAS:528:DC%2BD38Xhs1Cjtbw%3D 11842096
19. S Zimmermann S Glaser R Ketteler CF Waller U Klingmuller UM Martens 2004 Effects of telomerase modulation in human hematopoietic progenitor cells Stem Cells 22 741 749 10.1634/stemcells.22-5-741 1:CAS:528:DC%2BD2cXnvFOlurs%3D 15342938
20. P Grabowski M Hultdin K Karlsson G Tobin A Aleskog U Thunberg A Laurell C Sundstrom R Rosenquist G Roos 2005 Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status Blood 105 4807 4812 10.1182/blood-2004-11-4394 1:CAS:528:DC%2BD2MXlsVWisro%3D 15746080 (Pubitemid 40807307)
21. T Kondo N Oue K Yoshida Y Mitani K Naka H Nakayama W Yasui 2004 Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma Cancer Res 64 523 529 10.1158/0008-5472.CAN-03-1196 1:CAS:528:DC%2BD2cXmsVWrtA%3D%3D 14744765 (Pubitemid 38120891)